journal
Journals Journal of Thoracic Oncology

Journal of Thoracic Oncology

https://read.qxmd.com/read/38295954/ficonalkib-sy-3505-in-advanced-alk-positive-nsclc-a-multicenter-open-label-single-arm-phase-1-2-study
#21
JOURNAL ARTICLE
Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study.
Yuankai Shi, Xingsheng Hu, Xingya Li, Caifeng Gong, Ke Wang, Yongsheng Li, Shucai Zhang, Yongzhong Luo, Pingli Wang, Liyan Jiang, Xiangjiao Meng, Xiaorong Dong, Huijuan Wang, Runxiang Yang, Qi Mei, Baogang Liu, Limin Yang, Yinghui Sun
INTRODUCTION: Treatment options for second-generation (2nd -gen) ALK tyrosine kinase inhibitor (TKI)-resistant patients are limited. We evaluated the safety, pharmacokinetics, and efficacy of ficonalkib (SY-3505), a third-generation (3rd -gen) ALK TKI, in patients with advanced ALK-positive non-small cell lung cancer. METHODS: This first-in-human, phase 1/2 study (Chinese Clinical Trial Registry identifier: ChiCTR1900025619; ClinicalTrials.gov identifier: NCT05257512) had two parts...
38295954
January 29, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38280448/iruplinalkib-wx-0593-versus-crizotinib-in-alk-tki-na%C3%A3-ve-locally-advanced-or-metastatic-alk-positive-non-small-cell-lung-cancer-interim-analysis-of-a-randomized-open-label-phase-iii-study-inspire
#22
JOURNAL ARTICLE
Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naïve locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE).
Yuankai Shi, Jianhua Chen, Runxiang Yang, Hongbo Wu, Zhehai Wang, Weihua Yang, Jiuwei Cui, Yiping Zhang, Chunling Liu, Ying Cheng, Yunpeng Liu, Jinlu Shan, Donglin Wang, Lei Yang, Changlu Hu, Jian Zhao, Ranhua Cao, Bangxian Tan, Ke Xu, Meimei Si, Hui Li, Ruifeng Mao, Lingyan Li, Xiaoyan Kang, Lin Wang
BACKGROUND: Iruplinalkib (WX-0593) is a new-generation, potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) and has shown systemic and central nervous system (CNS) efficacy in ALK-positive non-small-cell lung cancer (NSCLC). We compared the efficacy and safety of iruplinalkib with crizotinib in ALK TKI-naïve, locally advanced or metastatic ALK-positive NSCLC patients. METHODS: In this open-label, randomized, multicenter, phase III study, patients with ALK-positive NSCLC were randomly assigned to receive iruplinalkib 180 mg once daily (7-day run-in at 60 mg once daily) or crizotinib 250 mg twice daily...
38280448
January 25, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38582549/correspondence-intensity-modulated-proton-therapy-versus-intensity-modulated-radiotherapy-for-inoperable-esophageal-squamous-cell-carcinoma-methodologic-issues
#23
LETTER
Correspondence: Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
Chia-Lun Chang, Kuan-Chou Lin, Wan-Ming Chen, Ben-Chang Shia, Szu-Yuan Wu
No abstract text is available yet for this article.
38582549
April 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38582548/intensity-modulated-proton-therapy-versus-intensity-modulated-radiotherapy-for-inoperable-esophageal-squamous-cell-carcinoma-methodologic-issues
#24
LETTER
Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
Chi-Chuan Chiou, Tzu-Yu Lai
No abstract text is available yet for this article.
38582548
April 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38582547/immunotherapy-is-a-good-standard-option-for-patients-with-malignant-pleural-mesothelioma-despite-the-real-world-results-from-australia
#25
EDITORIAL
Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia.
Illaa Smesseim, Paul Baas
No abstract text is available yet for this article.
38582547
April 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38582546/based-on-the-real-world-results-from-australia-immunotherapy-is-not-a-good-option-for-patients-with-mesothelioma
#26
EDITORIAL
Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma.
Steven G Gray, Tomer Meirson, Luciano Mutti
No abstract text is available yet for this article.
38582546
April 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38582545/lung-cancer-in-syria
#27
EDITORIAL
Lung Cancer in Syria.
Maher Saifo, Mousa Alali, Hazem Alhabeb, Mohammed Awak, Fouad Nahhat, Maha Manachi
No abstract text is available yet for this article.
38582545
April 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38582544/better-together-advancing-tobacco-use-treatment-and-lung-cancer-screening
#28
EDITORIAL
Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening.
Kimberly A Shoenbill, Adam O Goldstein
No abstract text is available yet for this article.
38582544
April 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38582543/additional-evidence-for-postoperative-radiation-therapy-on-thymic-carcinoma
#29
EDITORIAL
Additional Evidence for Postoperative Radiation Therapy on Thymic Carcinoma.
Zhengfei Zhu, Haiquan Chen
No abstract text is available yet for this article.
38582543
April 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38582542/translational-research-in-ros1-positive-nsclc-are-we-moving-out-of-the-six-blind-men-and-the-elephant-stage
#30
EDITORIAL
Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?
Jii Bum Lee, Misako Nagasaka
No abstract text is available yet for this article.
38582542
April 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38582541/incidental-pulmonary-nodules-an-opportunity-to-complement-lung-cancer-screening
#31
EDITORIAL
Incidental Pulmonary Nodules: An Opportunity to Complement Lung Cancer Screening.
Tracy L Leong, Annette McWilliams, Gavin M Wright
No abstract text is available yet for this article.
38582541
April 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38453331/response-to-letter-to-the-editor
#32
LETTER
Response to Letter to the Editor.
Mi Hee Cho, Jong Ho Cho, Dong Wook Shin
No abstract text is available yet for this article.
38453331
March 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38453330/how-does-rheumatoid-arthritis-increase-the-risk-of-lung-cancer
#33
LETTER
How Does Rheumatoid Arthritis Increase the Risk of Lung Cancer?
Bo-Guen Kim, Sanghyuk Yoon, Sun Yeop Lee, Jang Won Sohn, Dong Won Park
No abstract text is available yet for this article.
38453330
March 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38453329/response-to-letter-to-the-editor
#34
LETTER
Response to Letter to the Editor.
Nobuteru Kubo
No abstract text is available yet for this article.
38453329
March 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38453328/survival-and-prognosis-after-carbon-ion-radiotherapy-in-patients-with-nsclc
#35
LETTER
Survival and Prognosis After Carbon-Ion Radiotherapy in Patients With NSCLC.
Chen-Pi Li, Ru-Yin Tsai, Hui-Chin Chang, Shuo-Yan Gau
No abstract text is available yet for this article.
38453328
March 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38453327/lung-cancer-in-switzerland
#36
EDITORIAL
Lung Cancer in Switzerland.
Raphael Sven Werner, Alessandra Curioni-Fontecedro, Laetitia A Mauti, Alfredo Addeo, Solange Peters, Thomas Frauenfelder, Milo A Puhan, Martina Haberecker, Lukas Bubendorf, Tobias Finazzi, Matthias Guckenberger, Stefano Cafarotti, Thomas Geiser, Isabelle Opitz
No abstract text is available yet for this article.
38453327
March 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38453326/chemotherapy-and-osimertinib-combination-should-be-the-first-line-treatment-for-all-advanced-egfr-nsclc
#37
EDITORIAL
Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
Lanyi Nora Chen, Alexandria T M Lee, Misako Nagasaka, Sai-Hong Ignatius Ou
No abstract text is available yet for this article.
38453326
March 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38453325/chemotherapy-and-osimertinib-combination-should-not-be-the-first-line-treatment-for-all-advanced-egfr-nsclc
#38
EDITORIAL
Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
Sun Min Lim, Jii Bum Lee, Byoung Chul Cho
No abstract text is available yet for this article.
38453325
March 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38453324/considerations-for-enhancing-lung-cancer-risk-prediction-and-screening-in-asian-populations
#39
EDITORIAL
Considerations for Enhancing Lung Cancer Risk Prediction and Screening in Asian Populations.
Kevin Ten Haaf
No abstract text is available yet for this article.
38453324
March 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38453323/muc1-c-the-occam-razor-of-osimertinib-resistance
#40
EDITORIAL
MUC1-C: The Occam Razor of Osimertinib Resistance?
Anirudh Yalamanchali, Khaled A Hassan
No abstract text is available yet for this article.
38453323
March 2024: Journal of Thoracic Oncology
next page »
journal
journal
41363
2
3
Make the most of Read.
Download the mobile app.
Fetch more papers »
Fetching more papers... Fetching...

All material on this website is protected by copyright, Copyright © 1994-2024 1994-{new Date().getFullYear()} by WebMD LLC.

By using this service, you agree to our terms of use and privacy policy.

Do Not Sell My Personal Information  Your Privacy Choices

Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

╳

We want to hear from doctors like you!

Take a second to answer a survey question.

╳